UnitedHealth's Medicare Advantage Headwind Is Not in the Price

Medicare Advantage has been the growth engine for UnitedHealth for a decade. Enrollment growth averaged 8% per year through 2023. The margin structure was 4 to 5% on premiums, a meaningful contribution once scaled across 7 million lives.

The problem is that the member demographics have shifted. New enrollees are higher utilisation than the historical cohort. The aging Boomer wave is hitting age bands with materially higher medical cost intensity. Adding to that, the CMS reimbursement rate adjustments have not kept pace with the cost inflation.

The result is a structural compression in the MA margin that has already shown up in 2024 and 2025 results. Consensus modelling assumes the 2026 rate notice improves the picture. The data from the January 2026 CMS update does not support that assumption.

Historically, when healthcare payer margins compress for two consecutive years on utilisation-driven dynamics, the compression has averaged 200 to 300 basis points before stabilising. The cycle typically runs 8 to 10 quarters, not the 4 quarters the consensus models. The last comparable episode was the 2018-2019 compression that followed the ACA risk-corridor wind-down.

Consensus 2026 EPS of $30.80 assumes MCR of 85.5%, a 60 basis point improvement on 2025. If MCR holds at the 2025 level of 86.1%, EPS compresses by roughly $1.80. If MCR worsens by another 50 basis points, EPS drops to $27.

At the current multiple on a reset EPS number, the fair value moves to $430, roughly 12% downside. That is the range we think the stock settles into over the next 12 months.

The Optum business remains structurally healthy and provides a floor under the valuation. Optum Health generated roughly $100 billion of revenue in 2025 at high single digit operating margins. Optum Rx continues to grow at a mid single digit pace. These segments will continue to compound, but alone cannot hold up the consolidated earnings profile if insurance margins continue to compress.

The balance sheet holds roughly $30 billion of cash against $82 billion of debt. Net debt to EBITDA sits near 1.1x. The balance sheet is not a concern; the earnings trajectory is.